Trispecific antibodies produced from mAb2 pairs by controlled Fab-arm exchange.

HT <table frame="hsides"><colgroup><col align="left" /><col align="right" /><col align="right" /><col align="right" /><col align="right" /><col align="right" /></colgroup><thead><tr><th /><th>Theoretical mass</th><th>Observed mass</th><th>Difference in mass</th><th>Glycosylation</th><th>Mass error</th></tr><tr><th /><th colspan="5">(Da)</th></tr></thead><tbody><tr><td colspan="6">Parental antibodies</td></tr><tr><td>ANG-CT6 AC</td><td>147,930.6</td><td>150,802.3</td><td>2871.1</td><td>2xG0F</td><td>-19</td></tr><tr><td>BEV-CT6 BC</td><td>148,374.7</td><td>151,276.1</td><td>2901.4</td><td>2xG0F</td><td>+1</td></tr><tr><td colspan="6">Fab-arm exchanged antibody</td></tr><tr><td>ANG-CT6 AC*BEV-CT6 BC</td><td>148,157.6</td><td>151,040.6</td><td>2882.9</td><td>2xG0F</td><td>-7</td></tr></tbody></table> ht 2 G0F glycan: asialo-agalacto-fucosylated biantennary oligosaccharide. Keywords: antigen-binding Fc fragment; EGFR; heterodimer; multispecific antibodies; VEGF inhibition EN antigen-binding Fc fragment EGFR heterodimer multispecific antibodies VEGF inhibition 509 523 15 04/12/22 20220401 NES 220401 Introduction In the last two decades, bispecific antibodies have continuously enriched the spectrum of targeted therapies by showing activity in biological situations where their unique property of containing, in one molecule, specificities for two epitopes could surpass the results of single-agent-based approaches. The BCMA/CD200/CD16A specific antibody is a trispecific tetravalent "aTriFlex" antibody, a fusion protein featuring bivalent engagement of CD16A on the natural killer cells, and enhanced selectivity via the combination of two low-affinity binding single-chain antibodies for BCMA and CD200 ([8]). [Extracted from the article]